Bio-Rad amends credit agreement to add LIBOR fallback, expand EBITDA definition, increase debt/asset sale baskets

BIO-RAD LABORATORIES, INC.

Adds LIBOR replacement language to credit agreement; updates benchmark provisions.
Expands EBITDA to include non-recurring cash expenses (transaction costs, milestone payments, restructuring).
Provides unlimited cash and cash equivalent basket measured against leverage ratio, net of cash up to $200M globally.
Increases baskets for indebtedness, asset sales, cross-defaults, and judgment liens.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.